<DOC>
	<DOCNO>NCT01253928</DOCNO>
	<brief_summary>Non diabetic patient renal replacement therapy prone change body composition increase visceral fat muscle wasting favour insulin resistant state . Malnutrition associate bad prognosis patient . Glitazones powerful insulin sensitiser available clinical practice also anti-inflammatory property . Their use associate significant favourable change body fat distribution type 2 diabetic subject . Experimental study suggest glitazones may attenuate muscle waste renal failure . The goal study examine non diabetic ESRD patient effect pioglitazone inulin sensitivity protein metabolism determine hyperinsulinemic euglycemic clamp change body composition determine anthropometric measurement , dual energy X-ray absorptiometry ( DEXA ) CT-scan determine change abdominal visceral sub-cutaneous fat .</brief_summary>
	<brief_title>Pioglitazone , Body Composition , Insulin Sensitivity Protein Metabolism ESRD</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Non diabetic individual ESRD , hemodialysis peritoneal dialysis least 3 month . Consent form sign No infectious complication 3 month prior entry study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>body composition</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>protein metabolism</keyword>
	<keyword>pioglitazone</keyword>
</DOC>